iTeos Therapeutics Overview

  • Founded
  • 2011
Founded
  • Status
  • Public
  • Employees
  • 68
Employees
  • Stock Symbol
  • ITOS
Stock Symbol
  • Share Price
  • $22.77
  • (As of Tuesday Closing)

iTeos Therapeutics General Information

Description

ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therapeutics for patients. Its product candidates include EOS-850 which is an Adenosine A2A receptor-specific antagonist and EOS-448 which is an ADCC-enabled, anti-TIGIT immune checkpoint blocking antibody.

Contact Information

Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Biotechnology
Stock Exchange
NAS
Primary Office
  • Rue des Frères Wright 29
  • 6041 Gosselies
  • Belgium

iTeos Therapeutics Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

iTeos Therapeutics Stock Performance

(As of Tuesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$22.77 $24.48 $17.43 - $47.61 $799M 35.1M 434K -$1.39

iTeos Therapeutics Financials Summary

In Thousands,
USD
TTM 31-Mar-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018
EV 863,358 845,233
Revenue 0 0 0 0
EBITDA (46,177) (37,555) (21,724) (17,475)
Net Income (46,320) (38,033) (22,454) (18,057)
Total Assets 332,889 344,558 30,744 27,391
Total Debt 3,053 0 0 6,726
Public Fundamental Data provided by Morningstar, Inc. disclaimer

iTeos Therapeutics Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore iTeos Therapeutics‘s full profile, request access.

Request a free trial

iTeos Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore iTeos Therapeutics‘s full profile, request access.

Request a free trial

iTeos Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
ITeos Therapeutics Inc is a biopharmaceutical company engaged in the discovery and development of immuno-oncology therap
Drug Discovery
Gosselies, Belgium
68 As of 2021
00000
0000 0000-00-00
00000000 00000

00000000

et, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.
0000000000000
Newtown, PA
00 As of 0000
00000
00000000 00000

0000000

rud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in r
0000 000000000
San Diego, CA
000 As of 0000
00000
0000 0000-00-00
00000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

iTeos Therapeutics Competitors (37)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Onconova Therapeutics Formerly VC-backed Newtown, PA 00 00000 00000000 00000
0000000 0000000000 Formerly VC-backed San Diego, CA 000 00000 00000000 00000
000000000 Formerly VC-backed Gaithersburg, MD 00 00000 00000000 00000
00000000 Venture Capital-Backed San Carlos, CA 00 00000 00000000000 00000
000000 00000000000 Formerly VC-backed Burlingame, CA 00 00000 000000 - 000 00000
You’re viewing 5 of 37 competitors. Get the full list »

iTeos Therapeutics Executive Team (16)

Name Title Board Seat Contact Info
Michel Detheux Ph.D Chief Executive Officer & Board Member
Matthew Gall Chief Financial Officer, Finance & Chief Accounting Officer, Accounting
Matthew Call Chief Operating Officer, Operations
Alfred Gray Ph.D Director, Business Development
Benoît Van den Eynde Ph.D Co-Founder & Chairman, Scientific Committee
You’re viewing 5 of 16 executive team members. Get the full list »

iTeos Therapeutics Board Members (27)

Name Representing Role Since
Aaron Davis Boxer Capital Board Member 000 0000
Agustin Mohedas Ph.D Janus Henderson Investors Board Observer 000 0000
Ann Rhoads Self Board Member 000 0000
Benoît Van den Eynde Ph.D iTeos Therapeutics Co-Founder & Chairman, Scientific Committee 000 0000
Bruno Montanari Ph.D Self Board Member 000 0000
You’re viewing 5 of 27 board members. Get the full list »

iTeos Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

iTeos Therapeutics Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore iTeos Therapeutics‘s full profile, request access.

Request a free trial